# EDGAR Filing Document

**Accession Number:** 0001551152
**File Stem:** 0001558370-23-004206
**Filing Date:** 2023-3
**Character Count:** 5217
**Document Hash:** f9fae18d753f99f8f634b539a933a508
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-004206.hdr.sgml**: 20230320

**ACCESSION NUMBER**: 0001558370-23-004206

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230320

**DATE AS OF CHANGE**: 20230320

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AbbVie Inc.
- **CENTRAL INDEX KEY:** 0001551152
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 320375147
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35565
- **FILM NUMBER:** 23747043

**BUSINESS ADDRESS:**
- **STREET 1:** 1 NORTH WAUKEGAN ROAD
- **CITY:** NORTH CHICAGO
- **STATE:** IL
- **ZIP:** 60064
- **BUSINESS PHONE:** (847) 932-7900

**MAIL ADDRESS:**
- **STREET 1:** 1 NORTH WAUKEGAN ROAD
- **CITY:** NORTH CHICAGO
- **STATE:** IL
- **ZIP:** 60064

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of<br>the Securities Exchange Act of 1934 (Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;)**

---

| | |
|:---|:---|
| Filed by the Registrant ⌧ | Filed by the Registrant ⌧ |
| Filed by a Party other than the Registrant □ | Filed by a Party other than the Registrant □ |
| Check the appropriate box: | Check the appropriate box: |
| □ | Preliminary Proxy Statement |
| □ | **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** |
| □ | Definitive Proxy Statement |
| ⌧ | Definitive Additional Materials |
| □ | Soliciting Material under §240.14a-12 |
| **AbbVie Inc.** | **AbbVie Inc.** |
| (Name of Registrant as Specified In Its Charter) | (Name of Registrant as Specified In Its Charter) |
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) | (Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
| Payment of Filing Fee (Check the appropriate box): | Payment of Filing Fee (Check the appropriate box): |
| ⌧ | No fee required. |
| □ | Fee paid previously with preliminary materials. |
| □ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11 |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tmb-20230320xdefa14a_bg001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;V1.1 D95720-P86462 ABBVIE INC. 1 NORTH WAUKEGAN ROAD NORTH CHICAGO, IL 60064 Your Vote Counts! ABBVIE INC. 2023 Annual Meeting For holders as of March 6, 2023 Vote by May 4, 2023 11:59 PM ET. For shares held in a Plan, vote by May 2, 2023 11:59 PM ET. You invested in ABBVIE INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the Stockholder meeting to be held on May 5, 2023. Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 21, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting\* May 5, 2023 9:00 AM CT Virtually at: www.virtualshareholdermeeting.com/ABBV2023 \*Please check the meeting materials for any special requirements for meeting attendance. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tmb-20230320xdefa14a_bg002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D95721-P86462 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Voting Items Board Recommends For For For Against Against Against Against Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-delivery". 01) Robert J. Alpern 02) Melody B. Meyer 03) Frederick H. Waddell 1. Election of Class II Directors Nominees: 2. Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2023 3. Say on Pay – An advisory vote on the approval of executive compensation 4. Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate super majority voting 5. Stockholder Proposal – to Implement Simple Majority Vote 6. Stockholder Proposal – to Issue an Annual Report on Political Spending 7. Stockholder Proposal – to Issue an Annual Report on Lobbying 8. Stockholder Proposal – to Issue a Report on Patent Process For |

---